|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Novartis |
|---|---|
| Information provided by: | Novartis |
| ClinicalTrials.gov Identifier: | NCT00136773 |
Purpose
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.
| Condition | Intervention | Phase |
|---|---|---|
|
Albuminuria |
Drug: amlodipine/benazepril |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus |
| Estimated Enrollment: | 888 |
| Study Start Date: | April 2003 |
Eligibility| Ages Eligible for Study: | 21 Years to 85 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | CCIB002FUS12 |
| Study First Received: | August 25, 2005 |
| Last Updated: | March 20, 2008 |
| ClinicalTrials.gov Identifier: | NCT00136773 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Albuminuria Type 2 diabetes mellitus Hypertension |
|
Vasodilator Agents Albuminuria Metabolic Diseases Molecular Mechanisms of Pharmacological Action Urination Disorders Diabetes Mellitus Calcium Channel Blockers Endocrine System Diseases Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Protease Inhibitors Amlodipine Membrane Transport Modulators Urological Manifestations Signs and Symptoms Proteinuria Urologic Diseases Therapeutic Uses Diabetes Mellitus, Type 2 Benazepril Angiotensin-Converting Enzyme Inhibitors Glucose Metabolism Disorders |